37 results about "Blood cancers" patented technology

The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to an activator antigen expressed by blood cancer cells and an inhibitor receptor comprising an extracellular ligand binding domain specific to an inhibitor antigen expressed by non-cancerous blood cells.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

To provide a composition and method for targeted treatment of cancer such as blood cancer.SOLUTION: Disclosed are a CAR polypeptide including a target domain selectively binding to a B lymphocyte antigen (e.g., hematological malignant tumor, e.g., CD19, CD20, and / or CD22 antigen related to leukemia and / or lymphoma), and a chimeric antigen receptor (CAR) T-cell which expresses the polypeptide, and can be used together with an adoptive cell transfer. Also disclosed is a method for bringing antitumor immunity to a subject having blood cancer accompanied by adoptive transfer of a CAR T-cell.SELECTED DRAWING: None

A method of treating a blood cancer comprising the administration of therapeutically effective amounts of a phosphatidylinositol 3-kinase gamma (PI3Kg) inhibitor and an antimetabolite, optionally also a therapeutically effective amount of a BCL-2 inhibitor, to a patient in need thereof. A method of identifying a blood cancer patient susceptible to treatment with a PI3Kg inhibitor. A method of treating a blood cancer comprising administration of a therapeutically effective amount of a p-21-activated kinase 1 (PAK-1) inhibitor, optionally also a therapeutically effective amount of a BCL-2 inhibitor, to a patient in need thereof.

A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

Aspects of the disclosure relate to methods, systems, computer-readable storage media, and graphical user interfaces (GUIs) that are useful for characterizing subjects having certain cancers, for example solid tumor cancers or blood cancers. The disclosure is based, in part, on methods for determining a cytokine signature of a subject and the subject's prognosis and / or likelihood of responding to a therapy based upon the cytokine signature determination.

Several embodiments of the methods and compositions disclosed herein relate to immune cells engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cell expresses a chimeric receptor that targets a ligand of NKG2D on a tumor cell. In several embodiments, the cancer is a leukemia, e.g., acute myelogenous leukemia (e.g., recurrent / refractory acute myelogenous leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, such as breast cancer, cervical cancer, colorectal cancer, gastric cancer, head and neck cancer, hepatocellular cancer, lung cancer, melanoma, intrahepatic cholangiocarcinoma, or other liver tumor, such as a secondary metastatic tumor from colorectal cancer. In several embodiments, the immune cells are administered in combination with a therapeutic agent, such as an additional anti-cancer agent.

The present invention relates to: an affinity that specifically binds to the extracellular domain of CD137; a protein complex comprising the affinity and an antibody or an antigen-binding fragment thereof that specifically binds to a protein on the surface of cancer cells; and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. When using the affinity that specifically binds to CD137 according to the present invention, it is possible to develop a protein complex that specifically binds to antigens on the surfaces of various cancer cells while specifically binding to T cells, and thus can be effectively used in the prevention or treatment of leukemia and solid cancers.

A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

To provide anti-CD38 antibodies that may be used in the treatment of cancer, particularly solid and hematological cancers.SOLUTION: Provided is an anti-CD38 antibody having a particular sequence, or antigen-binding fragment thereof, the anti-CD38 antibody or antigen-binding fragment thereof exhibiting antibody-dependent cell-mediated cytotoxicity (ADCC) activity against CD38+ target cells, exhibiting no complement dependent cytotoxicity (CDC) or reduced CDC activity against CD38+ target cells as compared to Daratumumab under the same or substantially the same conditions, and inducing immune effector cell activation.SELECTED DRAWING: Figure 20

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The present invention relates to a compound of formula (I) wherein R1 represents a halogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a (C2-C6) alkenyl group, a (C1-C6) alkoxy group or a (C3-C6) cycloalkyloxy group, X and Y independently represent a-CH = group,-CR3 = group or-N = group, Z1 and Z2 independently represent a-CH2-group, an = CH-group or an = N-group, and R3 and R4 independently represent a hydrogen atom or a halogen atom, or any pharmaceutically acceptable salt thereof. The invention also relates to the use of the compounds as a medicament, in particular for the treatment and / or prevention of cancers, in particular cancers exhibiting recruitment of MDM2 to chromatin, the present invention relates to a cancer, more particularly a cancer selected from the group consisting of bone cancer, brain cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, leukemia (including acute myelogenous leukemia), pancreatic cancer, prostate cancer and liposarcoma, even more particularly a cancer selected from the group consisting of skin cancer, liposarcoma and leukemia, such as but not limited to liposarcoma, melanoma and acute myelogenous leukemia.

The invention discloses a polysubstituted amine compound, a pharmaceutical composition containing the polysubstituted amine compound and an application of the polysubstituted amine compound in tumor resistance. The structure of the polysubstituted amine compound is shown as a formula I in the specification. Through multiple experiments, the inventor of the invention proves that the compound disclosed by the invention has a remarkable inhibiting effect on FBXO44, and can be combined with the FBXO44 in cells to inhibit down-regulation of the FBXO44 on MTSS1, so that the formation of tumor cell microfilament skeletons is disturbed, and the compound has a strong anti-proliferation effect on gastric cancer cell strains such as NUGC4 and the like. Therefore, the compound disclosed by the invention can be used as an FBXO44 inhibitor to be applied to medicines for treating solid tumors or leukemia related to human or animal cell proliferation.

The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to an activator antigen expressed by blood cancer cells and an inhibitor receptor comprising an extracellular ligand binding domain specific to an inhibitor antigen expressed by non-cancerous blood cells.

The invention discloses a pyrrolo [2, 3-c] pyrazole compound as well as a preparation method and application thereof. The pyrrolo [2, 3-c] pyrazole compound has a structural formula as shown in a formula I: # imgabs0. The invention provides the pyrrolo [2, 3-c] pyrazole compound with a novel structure, and the compound has anti-tumor activity, especially for colon cancer, breast cancer, prostatic cancer and leukemia.

Clonal hematopoiesis is an age-related condition caused by somatic mutations conferring a clone-selective advantage to hematopoietic stem cells. Although clonal hematopoiesis is a benign disorder, the risk of developing leukemia, such as acute myeloid leukemia (AML), in an individual affected by clonal hematopoiesis is increased. In some aspects, the disclosure provides methods for inhibiting clonal hematopoiesis using senescent cell scavengers to target senescence of bone marrow stromal cells.

Provided herein are compositions for increasing apolipoprotein L1 (ApoL1) in a target cell. The ApoL1 may be a recombinant protein or an endogenous protein, optionally in a complex comprising ApoL1. Provided herein are antibodies and other binding molecules that specifically bind to apolipoprotein L1 (ApoL1) and haptoglobin associated protein (Hpr). In preferred embodiments, the antibodies and other molecules preferably bind to an ApoL1-containing complex, such as a trypanosomal cleavage factor (TLF), under physiological conditions. In preferred embodiments, the antibodies and antigen binding fragments are bispecific, trispecific, and multispecific molecules, which can bind to the ApoL1-containing complex and further bind to a cell specific antigen. Also provided are methods of using such molecules to increase flow of an ApoL1-containing complex into a target cell expressing the cell-specific antigen. Such an increase in ApoL-containing complexes may increase cell death. In a preferred embodiment, the target cell is a cancer cell, such as a blood cancer cell or a solid tumor cell.

Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-β-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention relates to novel compounds of formula (I): which are modulators of the serotonin receptor 1B (5-HTR1B), also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are useful in the treatment of diseases and conditions mediated by the 1B type serotonin receptor (5-HTR1B), such as cancer, including hematological cancers and solid tumors, respiratory diseases and liver diseases.

The present invention relates to new compounds of formula (1):as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

The features of the present disclosure are immunogenic XBP1-derived peptides, CD138-derived peptides, and CS1-derived peptides (and their pharmaceutical compositions), etc. The peptides can be used in a variety of methods, such as methods for inducing an immune response, methods for generating antibodies, and methods for treating cancer (e.g., breast cancer, colon cancer, pancreatic cancer, blood cancers, e.g., leukemia, or plasma cell disorders such as multiple myeloma or Waldenstrom macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, for example, in methods for treating pre-cancerous conditions such as smoldering multiple myeloma. The peptides can also be incorporated into MHC molecule multimer compositions and used, for example, in methods for detecting T cells in a cell population.

Described herein, in some aspects, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and / or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasizes to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed / refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer.

The present disclosure provides methods of treating leukemia, such as multiple myeloma, by administering a heterodimeric protein, such as XmAb24306, comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R [alpha] protein-Fc domain fusion, in combination with an FcRH5xCD3 bispecific antibody, such as a civorestat monoclonal antibody.

This disclosure relates to methods for treating hematological cancers (including resistant forms thereof). Also provided are methods for treating abnormally activated (or reactive) stroma, such as cancer stroma associated with hematological cancers, using an antibody or antigen-binding fragment thereof that is an inhibitor of the FBG region of tenascin C, to alter its state, for example, making it less tolerable to cancer cells and / or reducing treatment resistance caused by the stroma.

Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and / or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

To provide a physical therapeutic method as a method for treating hepatitis B virus, hepatitis C virus, leukemia, and malignant lymphoma.SOLUTION: There is provided a therapeutic system which implements a method for physically treating a pathogenic virus such as hepatitis virus, and hematologic cancers of leukemia and malignant lymphoma, in which a venous blood is taken out from a venous blood vessel using a silicone tube (1), after adding a heparin (2) the venous blood enters into a container (3) for heating at about 55°C to 60°C, an ozone (5) is added into the blood while circulating in a blood compatible metal tube (4), the blood flows out of the heating container (3) after the circulation and then the blood enters into the container (6) for returning the temperature back to the temperature about 1°C higher than an individual basal body temperature, the venous blood flows through the spread blood compatible metal tube (4), and the blood flows out of the container to return into a human body.SELECTED DRAWING: Figure 1

Disclosed herein are antibody-drug-conjugates (ADC) that allow for delivery and release of glucocorticoid receptor modulators into desired tissues. The disclosed ADCs include a peptide that facilitates the release of a glucocorticoid receptor modulator by legumain. The antibody-drug-conjugates are useful as therapeutic agents for treating various autoimmune disorders, inflammatory disorders, and blood cancers. Pharmaceutical compositions which include the ADCs are also disclosed, as are methods of treating autoimmune disorders, inflammatory disorders, and blood cancers by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat said disorders.